Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance
about
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
P2860
Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Self-administered C1 esterase ...... ability and patient acceptance
@ast
Self-administered C1 esterase ...... ability and patient acceptance
@en
Self-administered C1 esterase ...... ability and patient acceptance
@nl
type
label
Self-administered C1 esterase ...... ability and patient acceptance
@ast
Self-administered C1 esterase ...... ability and patient acceptance
@en
Self-administered C1 esterase ...... ability and patient acceptance
@nl
prefLabel
Self-administered C1 esterase ...... ability and patient acceptance
@ast
Self-administered C1 esterase ...... ability and patient acceptance
@en
Self-administered C1 esterase ...... ability and patient acceptance
@nl
P2860
P3181
P356
P1476
Self-administered C1 esterase ...... ability and patient acceptance
@en
P2093
Huamin (Henry) Li
P2860
P304
P3181
P356
10.2147/PPA.S86379
P407
P577
2016-09-07T00:00:00Z